FBLG · XBRL financial data

FibroBiologics financial statements, every quarter

The same tables from 11 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (FBLG's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	773*	960	975	1,213	1,356*	1,780	2,041	2,789	797*	2,953	1,658
General and administrative	1,707*	2,490	2,249	2,139	2,356*	2,751	2,449	2,249	1,793*	2,115	2,375
Total operating expenses	2,480*	3,450	3,224	3,352	3,712*	4,531	4,490	5,038	2,590*	5,068	4,033
Operating income (loss)	(2,480)*	(3,450)	(3,224)	(3,352)	(3,712)*	(4,531)	(4,490)	(5,038)	(2,590)*	(5,068)	(4,033)
Interest income	—	39	70	79	63*	99	50	73	25*	20	15
Interest expense	(81)*	4	5	5	6*	0	0	0	204*	4	7
Other income (expense)	0*	—	30	2	1*	0	(625)	0	6*	(2)	(92)
Income tax expense (benefit)	year only	—	—	0*	0*	0	0*	0*	0*	0	0*
Net income (loss)	(9,717)*	(8,460)	898	(500)	(3,099)*	(4,966)	(4,658)	(5,778)	(3,244)*	(5,000)	(4,117)
Earnings per share, basic‡ USD per share	(6.80)*	(5.40)	0.60	(0.20)	(1.80)*	(2.80)	(2.40)	(2.60)	—	(1.33)	(0.66)
Earnings per share, diluted‡ USD per share	(6.80)*	(5.40)	0.60	(0.20)	(1.80)*	(2.80)	(2.40)	(2.60)	—	(1.33)	(0.66)
Weighted average shares, basic‡ thousands of shares	1,412*	1,557	1,636	1,676	1,706*	1,834	1,932	2,154	—	3,773	6,273
Weighted average shares, diluted‡ thousands of shares	1,412*	1,557	1,636	1,676	1,706*	1,834	1,932	2,154	—	3,773	6,273

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (June 2026); filings made before it reported them unadjusted.

Fiscal quarters (FBLG's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	9,163	8,158	5,973	7,827	13,985	8,667	8,845	4,867	4,894	1,482	3,515
Total current assets	9,215	8,922	6,509	8,198	14,228	9,327	10,178	5,240	6,349	2,905	5,850
Property and equipment, net	797	770	799	772	824	814	967	908	842	776	710
Right-of-use asset	1,809	1,707	1,604	1,499	1,393	1,285	2,714	2,548	2,380	2,209	1,321
Total assets	11,821	11,399	8,912	10,469	16,445	11,426	13,907	8,744	9,619	5,938	7,929
Total current liabilities	9,183	13,985	10,132	6,677	12,726	8,211	10,964	6,722	1,759	1,829	2,213
Lease liability, non-current	1,385	1,277	1,167	1,055	984	865	2,083	1,897	1,704	1,509	1,080
Total liabilities	10,568	15,262	11,299	7,732	13,710	9,076	13,047	8,619	3,463	3,338	3,293
Accumulated deficit	(24,357)	(32,817)	(31,919)	(32,419)	(35,518)	(40,484)	(45,142)	(50,920)	(54,164)	(59,164)	(63,281)
Total stockholders' equity	1,253	(3,863)	(2,387)	2,737	2,735	2,350	860	125	6,156	2,600	4,636
Total liabilities and equity	11,821	11,399	8,912	10,469	16,445	11,426	13,907	8,744	9,619	5,938	7,929
Common shares outstanding (cover page)‡ thousands of shares	1,632	1,636	1,758	1,733	1,887	1,913	2,094	2,573	3,380	5,209	6,658

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (June 2026); filings made before it reported them unadjusted.

Fiscal quarters (FBLG's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(9,717)*	(8,460)	898	(500)	(3,099)*	(4,966)	(4,658)	(5,778)	(3,244)*	(5,000)	(4,117)
Stock-based compensation	432*	525	578*	572*	544*	551	729*	704*	702*	694	707*
Net cash from operating activities	(1,601)*	(4,275)	(1,947)*	(2,606)*	(3,073)*	(5,275)	(3,984)*	(3,972)*	(3,163)*	(4,364)	(3,291)*
Purchases of property and equipment	2*	8	66*	11*	99*	43	213*	6*	0*	0	0*
Net cash from investing activities	(2)*	(8)	(66)*	(11)*	(99)*	(43)	(213)*	(6)*	0*	0	0*
Proceeds from issuing common stock	—	2,819	0*	4,643*	45*	0	0*	—	year only	706	2,862*
Proceeds from issuing equity	year only	—	—	—	—	—	—	—	—	—	—
Net cash from financing activities	0*	3,278	(172)*	4,471*	9,330*	0	4,375*	0*	3,190*	952	5,324*
Net change in cash	(1,603)*	(1,005)	(2,185)*	1,854*	6,158*	(5,318)	178*	(3,978)*	27*	(3,412)	2,033*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
FibroBiologics	3,515	not reported	(3,291)*	6.7M	1.1 quarters	Q2 FY26 10-QJun 30, 2026
Dare Bioscience	12,618	188	(6,775)*	15.3M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Lunai Bioworks	1,714	31*	(1,841)*	5.0M	0.9 quarters	Q4 FY26 10-KJun 30, 2026
Imunon	6,864	not reported	(3,025)*	5.6M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Aptose Biosciences	1,020	not reported	(5,841)	2.6M	0.2 quarters	Q1 FY26 10-QMar 31, 2026
Armata Pharmaceuticals	23,952	not reported	(8,666)*	37.2M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Ovid Therapeutics	11,327	733	(17,594)*	195.3M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
Fibrogen	50,644	(1,474)	(3,991)*	4.0M	22.9 quarters	Q2 FY26 10-QJun 30, 2026
vTv Therapeutics	86,643	0	(11,443)*	not reported	7.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.